Scarica l'app Stockscreener
0.75
0.17%
-0.0013
Dopo l'orario di chiusura:
.76
0.01
+1.33%
Salarius Pharmaceuticals Inc Borsa (SLRX) Ultime notizie
What analysts say about Salarius Pharmaceuticals Inc. stockExceptional earning trajectories - PrintWeekIndia
Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia
What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com
Salarius Pharmaceuticals Modifies Security Holders’ Rights - TipRanks
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Australia
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - The Manila Times
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):